199 related articles for article (PubMed ID: 19370420)
1. Chemotherapy for ovarian cancer in the older adult.
Steer CB
Curr Treat Options Oncol; 2009 Aug; 10(3-4):159-70. PubMed ID: 19370420
[TBL] [Abstract][Full Text] [Related]
2. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
3. Impact of FRAilty screening and Geriatric assessment and INtervention in older patients with epithelial Ovarian Cancer: A multicenter randomized clinical trial protocol (FRAGINOC).
Daviu Cobián C; Oreskov JO; Blaakaer J; Jespersen E; Jørgensen TL; Ryg J; Herrstedt J; Høgdall C; Lund CM; Seibæk L; Vinther A; Ekmann-Gade AW; Schnack TH
J Geriatr Oncol; 2024 Apr; 15(3):101713. PubMed ID: 38326125
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
5. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
6. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.
Fanning J; Hilgers RD
Gynecol Oncol; 1993 Nov; 51(2):182-6. PubMed ID: 8276291
[TBL] [Abstract][Full Text] [Related]
7. GERiatric Screening in the treatment of elderly patients with Ovarian Carcinoma (GERSOC): study protocol for a pragmatic, cluster randomised controlled trial.
van Soolingen NJ; Smorenburg CH; Hamaker ME; Groen WG; Retèl VP; Lok CAR; van de Poll-Franse LV; Trum JW
Trials; 2020 Feb; 21(1):214. PubMed ID: 32087750
[TBL] [Abstract][Full Text] [Related]
8. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery.
Kim JS; Liang MI; Prendergast EN; Alldredge J; Datta A; Hurteau JA; Kirschner CV; Rodriguez G; Vogel TJ; Brooks RA; Cass I; Cohen JG; Penner KR; Wang CE; Diaz Moore ES
Int J Gynecol Cancer; 2019 Sep; 29(7):1156-1163. PubMed ID: 31352365
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.
Aabo K; Adams M; Adnitt P; Alberts DS; Athanazziou A; Barley V; Bell DR; Bianchi U; Bolis G; Brady MF; Brodovsky HS; Bruckner H; Buyse M; Canetta R; Chylak V; Cohen CJ; Colombo N; Conte PF; Crowther D; Edmonson JH; Gennatas C; Gilbey E; Gore M; Guthrie D; Yeap BY
Br J Cancer; 1998 Dec; 78(11):1479-87. PubMed ID: 9836481
[TBL] [Abstract][Full Text] [Related]
13. Platinum compounds and paclitaxel in advanced epithelial ovarian cancer.
Gadducci A; Brunetti I; Cosio S; Giannessi PG; Genazzani AR; Conte P
Anticancer Res; 1997; 17(6D):4703-8. PubMed ID: 9494592
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.
BMJ; 1991 Oct; 303(6807):884-93. PubMed ID: 1834291
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy for advanced ovarian cancer. Advanced Ovarian Cancer Trialists Group.
Stewart L;
Cochrane Database Syst Rev; 2000; (2):CD001418. PubMed ID: 10796788
[TBL] [Abstract][Full Text] [Related]
17. The effect of geriatric intervention in frail elderly patients receiving chemotherapy for colorectal cancer: a randomized trial (GERICO).
Lund CM; Vistisen KK; Dehlendorff C; Rønholt F; Johansen JS; Nielsen DL
BMC Cancer; 2017 Jun; 17(1):448. PubMed ID: 28659138
[TBL] [Abstract][Full Text] [Related]
18. Optimal primary therapy of ovarian cancer.
Bookman MA
Ann Oncol; 2016 Apr; 27 Suppl 1():i58-i62. PubMed ID: 27141074
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer.
van der Burg ME; Vergote I; Onstenk W; Boere IA; Leunen K; van Montfort CA; van Doorn HC
Eur J Cancer; 2013 Apr; 49(6):1254-63. PubMed ID: 23276720
[TBL] [Abstract][Full Text] [Related]
20. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.
Covens A; Carey M; Bryson P; Verma S; Fung Kee Fung M; Johnston M
Gynecol Oncol; 2002 Apr; 85(1):71-80. PubMed ID: 11925123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
